NeuroSense Therapeutics has announced a new development strategy for its ALS drug PrimeC, aiming to accelerate regulatory approval and reduce costs. The plan includes AI-driven analysis of PrimeC's unique formulation, a direct comparative trial against edaravone, and a streamlined Phase 3 study designed for earlier submission. This approach builds on positive Phase 2b data and seeks faster patient access, including a parallel regulatory pathway in Canada targeting approval by December 2026. The strategy aims to deliver a more efficient and compelling clinical package than traditional large trials.
Sandisk and Kioxia announced plans to invest over $31 billion in their memory manufacturing facilities in Japan. This investment represents about 60% of what they have spent there over the past 25 years, signaling a major expansion in their productio...
Nextech3D.AI reported a 101% increase in first-quarter revenue to $660,159, driven by a 47% rise in event technology sales and the launch of a new event experience and services segment. Gross profit rose 79% to $530,294, though net loss widened due t...
OpenAI has reportedly purchased tens of thousands of Apple Mac minis and Mac Studios to train AI agents, marking a shift in AI infrastructure from massive GPU clusters to distributed computing across many machines. Apple's unified-memory architecture...
POET Technologies, a small-cap photonics company specializing in optical engines for data centers, secured a $50 million purchase order from Lumilens, signaling strong growth potential in the AI data center market. Despite recent stock volatility and...
OpenAI announced its advertising business has reached a $1 billion annualized revenue run rate just 200 days after launch, supporting its diversified revenue model ahead of a major IPO. The company started testing ads in its ChatGPT chatbot in the U....
